IDXX vs VYNE · P/E 40, rev $2.36B vs rev $570.0K
IDEXX Laboratories Inc (IDXX) versus Vyne Therapeutics Inc (VYNE) — a side-by-side from cached financials, not a winner call.
IDEXX Laboratories Inc (IDXX) is a diagnostics & research company listed on NASDAQ.
Vyne Therapeutics Inc (VYNE) is a biotechnology company listed on NASDAQ.
Latest reported IDXX revenue for 2026-06-30 was $2.36B. Net income was $616.9M. IDXX currently screens at market cap $43.08B and trailing P/E 40.2.
Latest reported VYNE revenue for 2025-12-31 was $570.0K. Net income was -$26.5M. Revenue was up 13.8% from 2024-12-31 to 2025-12-31. VYNE currently screens at market cap $21.1M.
IDXX currently screens at market cap $43.08B and trailing P/E 40.2. VYNE currently screens at market cap $21.1M.
Not investment advice. Open the IDXX and VYNE stock pages for the full models.
Not investment advice.